Clinical Trial

A First-in-Human Study of PRD001

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of PRD001 in healthy participants and to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of PRD001 in participants with borderline/mild hyper-LDL-cholesterolemia and mild fatty liver.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-13.
Trial Details
NCT Number NCT07034183
Lead Sponsor PRD Therapeutics, Inc.
Conditions Healthy Volunteers
Enrollment 86 participants
Start Date 2025-06-19
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-07-30